Cargando…

The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden

SIMPLE SUMMARY: Patients diagnosed with stage II–III cutaneous melanoma (CM) are at high risk of recurrences, but the CM-specific survival ranges from approximately 40–70%. Here, the cure proportions and survival among uncured stage II–III CM patients were estimated. The 1- and 5-year relative survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Hanna, Utjés, Deborah, Olofsson Bagge, Roger, Gillgren, Peter, Isaksson, Karolin, Lapins, Jan, Schultz, Inkeri Leonardsson, Lyth, Johan, Andersson, Therese M.-L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158378/
https://www.ncbi.nlm.nih.gov/pubmed/34070092
http://dx.doi.org/10.3390/cancers13102456
_version_ 1783699874681716736
author Eriksson, Hanna
Utjés, Deborah
Olofsson Bagge, Roger
Gillgren, Peter
Isaksson, Karolin
Lapins, Jan
Schultz, Inkeri Leonardsson
Lyth, Johan
Andersson, Therese M.-L.
author_facet Eriksson, Hanna
Utjés, Deborah
Olofsson Bagge, Roger
Gillgren, Peter
Isaksson, Karolin
Lapins, Jan
Schultz, Inkeri Leonardsson
Lyth, Johan
Andersson, Therese M.-L.
author_sort Eriksson, Hanna
collection PubMed
description SIMPLE SUMMARY: Patients diagnosed with stage II–III cutaneous melanoma (CM) are at high risk of recurrences, but the CM-specific survival ranges from approximately 40–70%. Here, the cure proportions and survival among uncured stage II–III CM patients were estimated. The 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Proportions cured by surgery are low for sub-groups of stage II–III cutaneous melanoma showing that cure analyses can serve as a complement to established survival analyses. ABSTRACT: Background: Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival among uncured stage II–III cutaneous melanoma (CM) patients. Methods: 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Results: Stages IIB and IIC showed significant differences in standardized cure proportions vs. stage IIA CM (0.80 (95% CI 0.77–0.83) stage IIA; 0.62 (95% CI 0.59–0.66) stage IIB; 0.42 (95% CI 0.37–0.46) for stage IIC). Significant differences in standardized cure proportions were found for stages IIIB and IIIC-D CM vs. stage IIIA (0.76 (95% CI 0.68–0.84) stage IIIA; 0.52 (95% CI 0.45–0.59) stage IIIB; 0.35 (95% CI 0.30–0.39) for stage IIIC–D). Conclusions: The results are emphasizing the poor prognosis with low proportions cured by surgery only for sub-groups of stage II–III CM, specifically within stages IIB–C CM.
format Online
Article
Text
id pubmed-8158378
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81583782021-05-28 The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden Eriksson, Hanna Utjés, Deborah Olofsson Bagge, Roger Gillgren, Peter Isaksson, Karolin Lapins, Jan Schultz, Inkeri Leonardsson Lyth, Johan Andersson, Therese M.-L. Cancers (Basel) Article SIMPLE SUMMARY: Patients diagnosed with stage II–III cutaneous melanoma (CM) are at high risk of recurrences, but the CM-specific survival ranges from approximately 40–70%. Here, the cure proportions and survival among uncured stage II–III CM patients were estimated. The 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Proportions cured by surgery are low for sub-groups of stage II–III cutaneous melanoma showing that cure analyses can serve as a complement to established survival analyses. ABSTRACT: Background: Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival among uncured stage II–III cutaneous melanoma (CM) patients. Methods: 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Results: Stages IIB and IIC showed significant differences in standardized cure proportions vs. stage IIA CM (0.80 (95% CI 0.77–0.83) stage IIA; 0.62 (95% CI 0.59–0.66) stage IIB; 0.42 (95% CI 0.37–0.46) for stage IIC). Significant differences in standardized cure proportions were found for stages IIIB and IIIC-D CM vs. stage IIIA (0.76 (95% CI 0.68–0.84) stage IIIA; 0.52 (95% CI 0.45–0.59) stage IIIB; 0.35 (95% CI 0.30–0.39) for stage IIIC–D). Conclusions: The results are emphasizing the poor prognosis with low proportions cured by surgery only for sub-groups of stage II–III CM, specifically within stages IIB–C CM. MDPI 2021-05-18 /pmc/articles/PMC8158378/ /pubmed/34070092 http://dx.doi.org/10.3390/cancers13102456 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eriksson, Hanna
Utjés, Deborah
Olofsson Bagge, Roger
Gillgren, Peter
Isaksson, Karolin
Lapins, Jan
Schultz, Inkeri Leonardsson
Lyth, Johan
Andersson, Therese M.-L.
The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
title The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
title_full The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
title_fullStr The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
title_full_unstemmed The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
title_short The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
title_sort proportion cured of patients with resected stage ii–iii cutaneous melanoma in sweden
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158378/
https://www.ncbi.nlm.nih.gov/pubmed/34070092
http://dx.doi.org/10.3390/cancers13102456
work_keys_str_mv AT erikssonhanna theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT utjesdeborah theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT olofssonbaggeroger theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT gillgrenpeter theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT isakssonkarolin theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT lapinsjan theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT schultzinkerileonardsson theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT lythjohan theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT anderssonthereseml theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT erikssonhanna proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT utjesdeborah proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT olofssonbaggeroger proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT gillgrenpeter proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT isakssonkarolin proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT lapinsjan proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT schultzinkerileonardsson proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT lythjohan proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden
AT anderssonthereseml proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden